Know Cancer

or
forgot password

Genetic Mutation Analysis In A VHL Population


N/A
18 Years
N/A
Not Enrolling
Both
Kidney Cancer, Von Hippel-lindau Syndrome

Thank you

Trial Information

Genetic Mutation Analysis In A VHL Population


OBJECTIVES:

- Obtain laboratory identification and confirmation of research results for gene
mutations in participants previously enrolled in NCI-99-C-0053 who have von
Hippel-Lindau (VHL) syndrome or who are at risk for VHL syndrome.

- Determine genotype status in these participants.

OUTLINE: Participants submit a blood or buccal sample for genetic mutation analysis.
Participants may receive genetic counseling and/or the results of genetic testing, if
desired.

PROJECTED ACCRUAL: A maximum of 260 participants will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Prior enrollment in the von Hippel-Lindau (VHL) Syndrome Epidemiology Study
NCI-99-C-0053

- Meets 1 of the following criteria:

- Diagnosis of VHL syndrome

- At risk of VHL syndrome

- Family member of patient with VHL syndrome

- VHL syndrome genotype is not known

PATIENT CHARACTERISTICS:

Age

- Adult

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

William M. Linehan, MD

Investigator Role:

Study Chair

Investigator Affiliation:

NCI - Urologic Oncology Branch

Authority:

United States: Federal Government

Study ID:

030148

NCT ID:

NCT00075348

Start Date:

December 2003

Completion Date:

December 2008

Related Keywords:

  • Kidney Cancer
  • Von Hippel-lindau Syndrome
  • renal cell carcinoma
  • von Hippel-Lindau syndrome
  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Von Hippel-Lindau Disease

Name

Location

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesda, Maryland  20892-1182